RECRUITINGPhase 4INTERVENTIONAL
Clinical Study of ATTR-CM
Clinical Study Protocol of Transthyroxine Protein Amyloidosis Cardiomyopathy and Its Gene Carriers
About This Trial
In this study, patients with ATTR-CM or gene carriers were selected to study the diagnosis and treatment, and long-term follow-up was conducted.
Who May Be Eligible (Plain English)
Who May Qualify:
- Patients and gene carriers of ATTR-CM confirmed in the Second Affiliated Hospital of Zhejiang University School of Medicine, regardless of gender, age 18-90 years old;
- Patients who have the ability to understand the test and can cooperate with investigators
Who Should NOT Join This Trial:
- Patients who unable to understand or unwilling to fill in willing to sign a consent form forms or follow visitors
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Patients and gene carriers of ATTR-CM confirmed in the Second Affiliated Hospital of Zhejiang University School of Medicine, regardless of gender, age 18-90 years old;
* Patients who have the ability to understand the test and can cooperate with investigators
Exclusion Criteria:
* Patients who unable to understand or unwilling to fill in informed consent forms or follow visitors
Treatments Being Tested
DRUG
ATTR-CM
Current treatment
Locations (1)
xiaohong University PAN
Hangzhou, Zhejiang, China